Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
May 27, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
May 27, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update
May 07, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement HOUSTON, May 07, 2020 ...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2020 16:09 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
March 12, 2020 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
March 05, 2020 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2020 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...